QQ客服 官方微博 反馈留言

	Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
	Hu, Xi-Chun; Zhang, Jian; Xu, Bing-He; Cai, Li; Ragaz, Joseph; Wang, Zhong-Hua; Wang, Bi-Yun; Teng, Yue-E; Tong, Zhong-Sheng; Pan, Yue-Yin
刊名	LANCET ONCOLOGY
	2015
卷号	16期号:4
ISSN号	1470-2045
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4643286
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Hu, Xi-Chun,Zhang, Jian,Xu, Bing-He,et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. LANCET ONCOLOGY,2015,16(4).
APA	Hu, Xi-Chun.,Zhang, Jian.,Xu, Bing-He.,Cai, Li.,Ragaz, Joseph.,...&Shao, Zhi-Min.(2015).Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.LANCET ONCOLOGY,16(4).
MLA	Hu, Xi-Chun,et al."Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial".LANCET ONCOLOGY 16.4(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。